Yazar "Al-Taie, A." seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Assessment of vaccination pattern and intention to receive a boost dose of COVID vaccine among patients with chronic disease conditions(Springer, 2022) Al-Taie, A.; Yilmaz, Z. K.[Abstract Not Available]Öğe Disease and pharmacotherapy knowledge on Alzheimer's Disease among community pharmacists: a cross-sectional study from(Springer, 2022) Al-Taie, A.; Yilmaz, Z. K.[Abstract Not Available]Öğe Evaluation and prediction of depression and anxiety among patients with chronic disease conditions during the pandemic COVID-19 era(Springer, 2022) Al-Taie, A.; Khalaf, D. A. Mohd; Victoria, A. O.; Koseoglu, A.[Abstract Not Available]Öğe Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model(Ediciones Doyma, S.L., 2023) Al-Taie, A.; Yilmaz, Z.Background: Despite the fact that the WHO recommends that adults over the age of 18 have to receive a booster dose of the COVID-19 vaccine. The willingness and intention to accept a booster dose of the COVID-19 vaccine remain major issues among the general population, particularly patients with comorbid disease conditions. The aim of this study was to assess the patterns regarding COVID-19 infection and vaccination, along with the intention and hesitancy to receive a booster dose of the COVID-19 vaccine among patients with comorbid disease conditions in Istanbul, Türkiye. Methods: This was a descriptive, cross-sectional study conducted among patients with comorbid disease conditions using a three-part, structured, validated questionnaire. Vaccine hesitancy from a booster dose of the COVID-19 vaccine was assessed using the Health Belief Model (HBM), based on a 5-point Likert-type scale. Results: The study enrolled 162 participants with a mean age of 57.2 ± 13.3 years. 97% of the respondents received the COVID-19 vaccine. Almost half of respondents (51.2%) reported receiving information about a booster dose of the COVID-19 vaccine. HBM among the participants with comorbidities showed a significant agreement regarding the perceived susceptibility (P < 0.0001), perceived severity (P < 0.0001) and perceived benefits (P < 0.0001) to receive a booster vaccine dose. There was a statistically significant correlation between the intention to receive a booster vaccine dose and education level (university education; P < 0.0001). Conclusion: A vast and significant majority of patients with chronic comorbid disease conditions who received the COVID-19 vaccine reported an intention to receive a booster dose. © 2023 Elsevier España, S.L.U.Öğe Exploring the psychological impact of anxiety, depression, and quality of life in patients with comorbid disease conditions post COVID-19 pandemic era(Ediciones Doyma, S.L., 2024) Al-Taie, A.; Mohd Khalaf, D.A.; Arueyingho, O.Background: Chronic diseases and comorbidity are important predictors of depression and anxiety, the two most common disorders of poor mental health. Meanwhile, the pandemic increases anxiety and depression levels, alongside declined quality of life (QoL), the same way that comorbidities are associated with severity of COVID-19 progression. This study aimed to assess the prevalence of anxiety and depression, as well as the QoL among patients with chronic medical conditions in Amman, Jordan, in the post-pandemic period. Methods: A descriptive, cross-sectional study was conducted among patients with comorbidities using a validated questionnaire consisting of 3 parts. Anxiety and depression prevalence were assessed using the Hospital Anxiety and Depression Scale (HADS), while the QoL in terms of physical, psychological, social, emotional, and general mental health was evaluated using the SF-36 QoL questionnaire. Results: A total of 150 participants (mean age = 55 ± 13 years) were enrolled in the study. Most participants reported a significantly elevated level of borderline abnormal or mild anxiety (44%, P < .0001). The QoL scores indicated relatively poor well-being, particularly in the physical role (29.2 ± 45.5) and emotional role (26.2 ± 4.0) domains (P < .05). Statistical significance was observed between HADS anxiety or depression scores and variables, such as age, education level, and comorbidities. Conclusion: This study's findings provide insights into the adverse psychiatric consequences, high prevalence of anxiety and depressive symptoms, and reduced quality of life among patients with comorbid conditions post-COVID-19 pandemic. © 2023 Elsevier España, S.L.U.Öğe Impact of clinical pharmacist intervention on taxane-related lymphedema among breast cancer patients(Springer, 2022) Koseoglu, A.; Al-Taie, A.[Abstract Not Available]Öğe Intention and hesitancy to receive a booster COVID-19 dose among Turkish community pharmacists: a cross-sectional observational study(Springer, 2022) Al-Taie, A.; Yilmaz, Z. K.[Abstract Not Available]Öğe Patterns of knowledge and safety use of energy drinks use during COVID pandemic era among athletes and sport adolescents in Kyrenia-northern Cyprus(Springer, 2022) Al-Taie, A.; Victoria, A. O.; Koseoglu, A.[Abstract Not Available]Öğe Predicting acceptance and intention for receiving boost dose of covid vaccine among pregnant women using Health Belief model(Springer, 2022) Al-Taie, A.; Yilmaz, Z. K.; Cakiroglu, A. Y.; Candan, G.; Albayrak, N.[Abstract Not Available]
